FY2025 EPS Estimates for ACRV Boosted by Cantor Fitzgerald

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Acrivon Therapeutics in a research report issued on Wednesday, April 30th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($1.95) for the year, up from their prior estimate of ($2.55). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

A number of other analysts also recently issued reports on the stock. HC Wainwright cut their price target on shares of Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. KeyCorp began coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $21.80.

Acrivon Therapeutics Stock Up 6.0 %

NASDAQ ACRV opened at $1.41 on Friday. The business’s fifty day simple moving average is $3.20 and its 200-day simple moving average is $5.43. The firm has a market cap of $44.21 million, a PE ratio of -0.52 and a beta of 1.77. Acrivon Therapeutics has a 52 week low of $1.30 and a 52 week high of $10.16.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.09.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp raised its stake in shares of Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after buying an additional 47,233 shares during the last quarter. Barclays PLC boosted its stake in shares of Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after purchasing an additional 28,748 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Acrivon Therapeutics during the 4th quarter worth about $40,000. Finally, American Century Companies Inc. lifted its stake in shares of Acrivon Therapeutics by 14.2% during the fourth quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock valued at $106,000 after buying an additional 2,186 shares during the period. Institutional investors and hedge funds own 71.62% of the company’s stock.

Insider Buying and Selling

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc sold 437,881 shares of the firm’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $1.41, for a total value of $617,412.21. Following the completion of the sale, the insider now owns 3,403,025 shares of the company’s stock, valued at approximately $4,798,265.25. This trade represents a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 1,707,833 shares of company stock valued at $3,009,858 over the last quarter. 8.50% of the stock is currently owned by insiders.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.